Studies reviewed herein include intracorneal AAV-HLA-G administration to inhibit corneal inflammation and vascularization, ex vivo AAV incubation of corneal grafts to prevent corneal transplant rejection, subconjunctival injection of AAV-HLA-G for dry eye and ocular graft vs. host disease, and intravitreal injection of AAV-HLA-G to inhibit uveitis (Table 1). This evidence concerns the gene HLA-G and dry eye syndrome.